FATE Fundamental Analysis - FATE THERAPEUTICS INC

Name: FATE THERAPEUTICS INC (FATE) Stock
Brand: FATE THERAPEUTICS INC
Rating: 4 (3 reviews)

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to FATE. FATE was compared to 533 industry peers in the Biotechnology industry. While FATE seems to be doing ok healthwise, there are quite some concerns on its profitability. FATE is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year FATE has reported negative net income.

In the past year FATE has reported a negative cash flow from operations.

In the past 5 years FATE always reported negative net income.

In the past 5 years FATE always reported negative operating cash flow.

1.2 Ratios

The Return On Assets of FATE (-46.15%) is comparable to the rest of the industry.

With a Return On Equity value of -65.63%, FATE perfoms like the industry average, outperforming 58.91% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-46.15%
ROE	-65.63%
ROIC	N/A

ROA(3y)-37.99%

ROA(5y)-32.97%

ROE(3y)-53.45%

ROE(5y)-47.34%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for FATE so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

FATE does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for FATE has been increased compared to 1 year ago.

FATE has more shares outstanding than it did 5 years ago.

There is no outstanding debt for FATE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

FATE has an Altman-Z score of -5.83. This is a bad value and indicates that FATE is not financially healthy and even has some risk of bankruptcy.

FATE has a Altman-Z score of -5.83. This is in the lower half of the industry: FATE underperforms 63.79% of its industry peers.

There is no outstanding debt for FATE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-5.83

ROIC/WACCN/A

WACC8.78%

2.3 Liquidity

FATE has a Current Ratio of 8.04. This indicates that FATE is financially healthy and has no problem in meeting its short term obligations.

With a decent Current ratio value of 8.04, FATE is doing good in the industry, outperforming 73.92% of the companies in the same industry.

A Quick Ratio of 8.04 indicates that FATE has no problem at all paying its short term obligations.

FATE has a better Quick ratio (8.04) than 73.92% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	8.04
Quick Ratio	8.04

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

FATE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.20%, which is quite good.

The Revenue for FATE has decreased by -31.21% in the past year. This is quite bad

The Revenue has been growing slightly by 5.00% on average over the past years.

EPS 1Y (TTM)15.2%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%12.12%

Revenue 1Y (TTM)-31.21%

Revenue growth 3Y-37.51%

Revenue growth 5Y5%

Sales Q2Q%-71.84%

3.2 Future

Based on estimates for the next years, FATE will show a small growth in Earnings Per Share. The EPS will grow by 4.57% on average per year.

FATE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 49.95% yearly.

EPS Next Y27.41%

EPS Next 2Y12.38%

EPS Next 3Y11.32%

EPS Next 5Y4.57%

Revenue Next Year-50.5%

Revenue Next 2Y-35.06%

Revenue Next 3Y-27.95%

Revenue Next 5Y49.95%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

FATE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year FATE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y12.38%

EPS Next 3Y11.32%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for FATE!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

FATE THERAPEUTICS INC

NASDAQ:FATE (11/17/2025, 6:00:23 PM)

After market: 0.98 +0.01 (+1.03%)

0.97

+0.01 (+0.62%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)10-30 2025-10-30/amc

Earnings (Next)03-03 2026-03-03/amc

Inst Owners78.65%

Inst Owner Change-4.14%

Ins Owners1.5%

Ins Owner Change0.46%

Market Cap111.87M

Revenue(TTM)8.47M

Net Income(TTM)-171.52M

Analysts78.89

Price Target4.74 (388.66%)

Short Float %6.66%

Short Ratio3.57

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)17.53%

Min EPS beat(2)16.98%

Max EPS beat(2)18.09%

EPS beat(4)4

Avg EPS beat(4)11.15%

Min EPS beat(4)0.25%

Max EPS beat(4)18.09%

EPS beat(8)8

Avg EPS beat(8)14.84%

EPS beat(12)12

Avg EPS beat(12)19.87%

EPS beat(16)15

Avg EPS beat(16)17.24%

Revenue beat(2)2

Avg Revenue beat(2)62.4%

Min Revenue beat(2)39.83%

Max Revenue beat(2)84.97%

Revenue beat(4)4

Avg Revenue beat(4)70.24%

Min Revenue beat(4)28.81%

Max Revenue beat(4)127.37%

Revenue beat(8)8

Avg Revenue beat(8)104.71%

Revenue beat(12)10

Avg Revenue beat(12)80.93%

Revenue beat(16)14

Avg Revenue beat(16)77.32%

PT rev (1m)4.49%

PT rev (3m)-13.17%

EPS NQ rev (1m)-0.56%

EPS NQ rev (3m)13.46%

EPS NY rev (1m)-1.74%

EPS NY rev (3m)12.96%

Revenue NQ rev (1m)-0.13%

Revenue NQ rev (3m)52.04%

Revenue NY rev (1m)-0.01%

Revenue NY rev (3m)39.7%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	13.21
P/FCF	N/A
P/OCF	N/A
P/B	0.43
P/tB	0.43
EV/EBITDA	N/A

EPS(TTM)-1.45

EYN/A

EPS(NY)-1.21

Fwd EYN/A

FCF(TTM)-1.03

FCFYN/A

OCF(TTM)-1

OCFYN/A

SpS0.07

BVpS2.27

TBVpS2.27

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-46.15%
ROE	-65.63%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-37.99%

ROA(5y)-32.97%

ROE(3y)-53.45%

ROE(5y)-47.34%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score2

Asset Turnover0.02

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	19.66%
Cap/Sales	37.2%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	8.04
Quick Ratio	8.04
Altman-Z	-5.83

F-Score2

WACC8.78%

ROIC/WACCN/A

Cap/Depr(3y)98.67%

Cap/Depr(5y)264.44%

Cap/Sales(3y)17.33%

Cap/Sales(5y)31.69%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)15.2%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%12.12%

EPS Next Y27.41%

EPS Next 2Y12.38%

EPS Next 3Y11.32%

EPS Next 5Y4.57%

Revenue 1Y (TTM)-31.21%

Revenue growth 3Y-37.51%

Revenue growth 5Y5%

Sales Q2Q%-71.84%

Revenue Next Year-50.5%

Revenue Next 2Y-35.06%

Revenue Next 3Y-27.95%

Revenue Next 5Y49.95%

EBIT growth 1Y9.14%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year32.17%

EBIT Next 3Y-7.64%

EBIT Next 5YN/A

FCF growth 1Y43.05%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y38.43%

OCF growth 3YN/A

OCF growth 5YN/A

FATE THERAPEUTICS INC / FATE FAQ

Can you provide the ChartMill fundamental rating for FATE THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to FATE.

What is the valuation status for FATE stock?

ChartMill assigns a valuation rating of 0 / 10 to FATE THERAPEUTICS INC (FATE). This can be considered as Overvalued.

What is the profitability of FATE stock?

FATE THERAPEUTICS INC (FATE) has a profitability rating of 1 / 10.

Can you provide the expected EPS growth for FATE stock?

The Earnings per Share (EPS) of FATE THERAPEUTICS INC (FATE) is expected to grow by 27.41% in the next year.

FATE THERAPEUTICS INC (FATE) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

FATE THERAPEUTICS INC / FATE FAQ

Can you provide the ChartMill fundamental rating for FATE THERAPEUTICS INC?

What is the valuation status for FATE stock?

What is the profitability of FATE stock?

Can you provide the expected EPS growth for FATE stock?